MENU

Why the CogState Limited share price rocketed a massive 27% today

One of the biggest movers on the market today has been the CogState Limited (ASX: CGS) share price.

In afternoon trade the cognitive science company’s shares are up a remarkable 27% to $1.06.

Why has it jumped?

Although there has been no news out of the company today, it appears as though this gain is a delayed reaction to a big announcement CogState released at the end of last week.

That announcement revealed that the company has been chosen as a preferred provider to healthcare giant Eli Lilly and Company to support its Alzheimer’s disease platform.

This means that CogState will look to leverage its technology to provide solutions that ensure high-quality neuropsychological outcome measures in clinical trials.

Together the two companies will deploy “an innovative program to improve the way that research sites train and collect endpoint data across Lilly’s portfolio of Alzheimer’s disease studies.”

Should you invest?

Whilst this is undoubtedly big news for this fledgling company, it is perhaps a little too soon to get overly excited.

At this stage CogState has merely being designated a preferred provider, it does not constitute an award of new business just yet.

But considering the growing demand for its technology from pharmaceutical companies, I wouldn’t be too surprised to see the company awarded business from Eli Lilly in the near future.

But until that happens I would suggest investors hold off an investment. Especially with its shares trading at 56x annualised earnings.

At this point in time I think investors would get better value for money with investments in fellow medical technology shares Nanosonics Ltd. (ASX: NAN) and Fisher & Paykel Healthcare Corp Ltd (ASX: FPH).

So rather than risk your hard-earned money in CogState, I would suggest you look at Nanosonics and Fisher & Paykel Healthcare or consider an investment in one of these stunning blue-chip shares. I'm tipping each of them for BIG gains this year.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia owns shares of Nanosonics Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

HOT OFF THE PRESSES: My #1 Dividend Pick for 2017!

With its shares up 155% in just the last five years, this ‘under the radar’ consumer favourite is both a hot growth stock AND our expert’s #1 dividend pick for 2017. Now we’re pulling back the curtain for you... And all you have to do to discover the name, code and a full analysis is enter your email below!

Simply enter your email now to receive your copy of our brand-new FREE report, “The Motley Fool’s Top Dividend Stock for 2017.”

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.